Last reviewed · How we verify
Placebo to L50/H12.5
This is a placebo control arm in a clinical trial comparing a fixed-dose combination of L50/H12.5 against placebo.
At a glance
| Generic name | Placebo to L50/H12.5 |
|---|---|
| Sponsor | Merck Sharp & Dohme LLC |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
The designation 'Placebo to L50/H12.5' indicates this is a phase 3 trial arm where patients receive placebo, likely with the intent to transition or compare to an active treatment containing L50 and H12.5 components. Without identification of the specific active compounds, the precise mechanism cannot be determined.
Approved indications
Common side effects
Key clinical trials
- A Long-term Study of the Safety of MK-0954A in Patients With Essential Hypertension (MK-0954A-351) (PHASE3)
- MK-0954E Study in Participants With Hypertension (MK-0954E-357) (PHASE3)
- MK-0954E Phase III Long-Term Study in Participants With Hypertension (MK-0954E-356) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo to L50/H12.5 CI brief — competitive landscape report
- Placebo to L50/H12.5 updates RSS · CI watch RSS
- Merck Sharp & Dohme LLC portfolio CI